Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02589-x ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yoichi Naito und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. ynaito@east.ncc.go…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Sacituzumab govitecan (SG) is a Trop-2–directed antibody–drug conjugate approved outside Japan for second-line and later metastatic triple-negative breast cancer (mTNBC), based on the ASCENT study (NCT02574455). We report SG safety and efficacy in an open-label, phase 1/2 bridging study in Japanese patients with advanced solid tumors (ASCENT-J02; NCT05101096; jRCT2031210346).
Methods
Phase 1 was a standard 3 + 3 design. Patients received intravenous SG 6 mg/kg, escalating to 10 mg/kg, on Days 1 and 8 per 21-day cycle; primary endpoints were safety, incidence of dose-limiting toxicity/toxicities (DLTs), and determination of the recommended phase 2 dose (RP2D). In the multicohort phase 2 study, patients in the mTNBC cohort with previously treated disease received SG at the RP2D; primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR; RECIST v1.1). Safety was a secondary endpoint.
Results
In phase 1 ( N = 15), one DLT (grade 3 elevated transaminases) occurred with SG 10 mg/kg; RP2D was SG 10 mg/kg regardless of UGT1A1 status. In phase 2, 36 patients with mTNBC received SG 10 mg/kg. At median follow-up of 6.1 months, IRC-assessed ORR was 25.0% (95% CI 12.1–42.2; P = 0.0077). Median progression-free survival was 5.6 months (95% CI 3.9–not reached [NR]); median overall survival was NR. No treatment-emergent adverse events led to discontinuation or death.
Conclusions
SG RP2D was established as 10 mg/kg in Japanese patients. SG showed efficacy in Japanese patients with previously treated mTNBC, a manageable safety profile, and no new safety signals, consistent with the previous ASCENT study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. ynaito@east.ncc.go.jp.
- Showa University Hospital, Tokyo, Japan.
- Kyoto University Hospital, Kyoto, Japan.
- Tohoku University Hospital, Miyagi, Japan.
- Osaka International Cancer Institute, Osaka, Japan.
- Kumamoto University Hospital, Kumamoto, Japan.
Förderung
- Gilead Sciences
Zitieren
APA
Naito, Y., Nakamura, S., Kawaguchi-Sakita, N., Ishida, T., Nakayama, T., Yamamoto, Y., Masuda, N., Matsumoto, K., Kogawa, T., Sudo, K., Shimomura, A., Lai, C., Zhang, D., Iwahori, Y., Gary, D., Huynh, D., & Iwata, H. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02589-x
Vancouver
Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, et al. Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02589-x
BibTeX
@article{Naito2024,
author = {Naito, Yoichi and Nakamura, Seigo and Kawaguchi-Sakita, Nobuko and Ishida, Takanori and Nakayama, Takahiro and Yamamoto, Yutaka and Masuda, Norikazu and Matsumoto, Koji and Kogawa, Takahiro and Sudo, Kazuki and Shimomura, Akihiko and Lai, Catherine and Zhang, Danjie and Iwahori, Yuki and Gary, Dianna and Huynh, Danh and Iwata, Hiroji},
title = {Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02589-x}
}
EUVIMED